Insider Transactions in Q4 2021 at Prelude Therapeutics Inc (PRLD)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 15
2021
|
Deborah Morosini EVP, Chief of Clinical Affairs |
SELL
Open market or private sale
|
Direct |
28,751
-98.48%
|
$373,763
$13.0 P/Share
|
|
Dec 15
2021
|
Deborah Morosini EVP, Chief of Clinical Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
28,751
+46.71%
|
$201,257
$7.37 P/Share
|
|
Dec 14
2021
|
Andrew Combs Chief Chemistry Officer |
BUY
Open market or private purchase
|
Direct |
4,000
+1.47%
|
$44,000
$11.6 P/Share
|
|
Dec 13
2021
|
Andrew Combs Chief Chemistry Officer |
BUY
Open market or private purchase
|
Direct |
4,000
+1.49%
|
$48,000
$12.12 P/Share
|
|
Dec 13
2021
|
Krishna Vaddi CEO |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+0.75%
|
$96,000
$12.13 P/Share
|
|
Dec 13
2021
|
Laurent Chardonnet Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+38.46%
|
$60,000
$12.28 P/Share
|
|
Nov 16
2021
|
Deborah Morosini EVP, Chief of Clinical Affairs |
SELL
Open market or private sale
|
Direct |
28,751
-72.25%
|
$460,016
$16.15 P/Share
|
|
Nov 16
2021
|
Deborah Morosini EVP, Chief of Clinical Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
28,751
+49.62%
|
$345,012
$12.85 P/Share
|
|
Oct 05
2021
|
David J Mauro Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,000
-75.07%
|
$465,000
$31.21 P/Share
|
|
Oct 05
2021
|
David J Mauro Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$15,000
$1.89 P/Share
|